Aravive, Inc.
(NASDAQ : VSAR)

( )
VSAR PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
-1.94%88.651.3%$803.98m
AMGNAmgen Inc.
-0.76%185.501.2%$628.99m
GILDGilead Sciences, Inc.
-2.14%65.550.9%$482.29m
BIIBBiogen Inc.
-4.17%321.171.3%$427.44m
ILMNIllumina, Inc.
-1.77%296.883.5%$311.35m
REGNRegeneron Pharmaceuticals, Inc.
-0.92%418.622.6%$290.18m
VRTXVertex Pharmaceuticals Incorporated
-2.55%183.061.9%$253.58m
ALXNAlexion Pharmaceuticals, Inc.
-1.76%127.552.0%$219.68m
SRPTSarepta Therapeutics, Inc.
-2.87%136.5415.4%$152.33m
AAgilent Technologies, Inc.
-0.83%77.911.6%$150.84m
EXASExact Sciences Corporation
-0.42%83.2825.3%$132.28m
INCYIncyte Corporation
-0.49%83.332.5%$111.93m
ARRYArray BioPharma Inc.
-1.99%22.718.2%$108.01m
EXELExelixis, Inc.
-0.09%21.226.4%$82.07m
NBIXNeurocrine Biosciences, Inc.
-2.58%77.315.1%$77.22m

Company Profile

Aravive, Inc. is a clinical stage biotechnology company focused on developing innovative therapies that target treatment for cancer. Its product portfolio include AVB-S6-500 which is a soluble Fc-fusion protein designed to block the activation of the GAS6-AXL signaling pathway by intercepting the binding of GAS6 to its receptor AXL which also promotes metastasis, cancer cell survival, resistance to treatments, and immune suppression. The company was founded on July 6, 2016 and is headquartered in Houston, TX.